XFOR analyst estimates
X4 Pharmaceuticals (XFOR) analyst ratings, the average price target and its range, and every firm's latest call.
- 1 firms rate XFOR: 1 buy, 0 hold, 0 sell.
- The average price target is $11.50 from None analysts, from $11.00 to $12.00.
XFOR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | X4 Pharmaceuticals initiated with an Overweight at Wells Fargo | $11.00 |
| Jun 2, 2026 | Leerink Partners | X4 Pharmaceuticals initiated with an Outperform at Leerink | $12.00 |
| Mar 9, 2026 | Guggenheim | X4 Pharmaceuticals initiated with a Buy at Guggenheim | $12.00 |
| Dec 5, 2025 | Stifel Nicolaus | X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel | $10.00 |
| Nov 5, 2025 | Stifel Nicolaus | X4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel | $7.50 |
| Aug 29, 2025 | Stifel Nicolaus | X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel | $9.00 |
| Aug 13, 2025 | H.C. Wainwright | X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright | $3.50 |
| Dec 22, 2022 | Cantor Fitzgerald | Cantor Fitzgerald Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $3 | $3.00 |
| Dec 11, 2022 | Piper Sandler | X4 Pharmaceuticals initiated with an Overweight at Piper Sandler | $3.00 |
| Nov 30, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5 | $5.00 |